Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibElias Jabbour, H. Kantarjian, Elza Lomaia et al.|JAMA Oncology|2024Cited by 26
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid TumorsNehal J. Lakhani, Yifan Zhai, Drew Rasco et al.|Clinical Cancer Research|2023Cited by 24